These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Levin VA; Edwards MS; Wright DC; Seager ML; Schimberg TP; Townsend JJ; Wilson CB Cancer Treat Rep; 1980; 64(2-3):237-44. PubMed ID: 7407756 [TBL] [Abstract][Full Text] [Related]
50. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide. Rinne ML; Wen PY Oncology (Williston Park); 2015 Apr; 29(4):265, 275. PubMed ID: 25952491 [No Abstract] [Full Text] [Related]
52. Sarcoid-like reaction in a child following prolonged therapeutic exposure to dabrafenib and trametinib for BRAF V600E mutated hypothalamic/chiasmatic glioma. Wilhelmsson M; Chun FJ; Yeung RSM; Krtizinger F; McKeown T; Coblentz A; Ertl-Wagner B; Tabori U; Bartels U; Das A Pediatr Blood Cancer; 2023 Nov; 70(11):e30619. PubMed ID: 37555268 [No Abstract] [Full Text] [Related]
53. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438 [TBL] [Abstract][Full Text] [Related]
54. Chemotherapy for diffuse low-grade gliomas in adults. Ducray F Rev Neurol (Paris); 2011 Oct; 167(10):673-9. PubMed ID: 21906770 [TBL] [Abstract][Full Text] [Related]
55. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF Ellison DW; Hawkins C; Jones DTW; Onar-Thomas A; Pfister SM; Reifenberger G; Louis DN Acta Neuropathol; 2019 Apr; 137(4):683-687. PubMed ID: 30848347 [No Abstract] [Full Text] [Related]
56. Response and control: lessons from oligodendroglioma. Cairncross JG; Eisenhauer EA J Clin Oncol; 1995 Sep; 13(9):2475-6. PubMed ID: 7666112 [No Abstract] [Full Text] [Related]
57. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Triebels VH; Taphoorn MJ; Brandes AA; Menten J; Frenay M; Tosoni A; Kros JM; Stege EB; Enting RH; Allgeier A; van Heuvel I; van den Bent MJ Neurology; 2004 Sep; 63(5):904-6. PubMed ID: 15365146 [TBL] [Abstract][Full Text] [Related]
58. Medical Research Council adjuvant trial in high-grade gliomas. Chamberlain MC; Jaeckle KA J Clin Oncol; 2001 Oct; 19(19):3997-9. PubMed ID: 11579124 [No Abstract] [Full Text] [Related]
59. Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas. Jeremic B; Jovanovic D; Djuric LJ; Jevremovic S; Mijatovic LJ J Chemother; 1992 Apr; 4(2):123-6. PubMed ID: 1321239 [TBL] [Abstract][Full Text] [Related]